144 related articles for article (PubMed ID: 2764813)
1. The metabolism of C3 and C4 in patients with immune complexes and normal complement levels.
Charlesworth JA; Peake PW; Golding J; Pussell BA; Timmermans V; Wicks I; Wakefield D
Aust N Z J Med; 1989 Apr; 19(2):118-24. PubMed ID: 2764813
[TBL] [Abstract][Full Text] [Related]
2. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
Charlesworth JA; Peake PW; Golding J; Mackie JD; Pussell BA; Timmermans V; Wakefield D
Ann Rheum Dis; 1989 Feb; 48(2):153-9. PubMed ID: 2784659
[TBL] [Abstract][Full Text] [Related]
3. The effect of antibody isotype on the activation of C3 and C4 by immune complexes formed in the presence of serum: correlation with the prevention of immune precipitation.
Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
Mol Immunol; 1990 May; 27(5):423-8. PubMed ID: 2366759
[TBL] [Abstract][Full Text] [Related]
4. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
Garred P; Michaelsen TE; Aase A; Mollnes TE
J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
[TBL] [Abstract][Full Text] [Related]
5. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K
Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790
[TBL] [Abstract][Full Text] [Related]
6. Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis.
Perrin LH; Nydegger UE; Zubler RH; Lambert PH; Miescher PA
Arthritis Rheum; 1977 Mar; 20(2):647-52. PubMed ID: 849359
[TBL] [Abstract][Full Text] [Related]
7. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
8. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
9. Circulating immune complexes, complement factors C3, C4, C1-inhibitor, alpha-1-antitrypsin and immunoglobulins in asthmatic patients.
Häfner GE; Wüthrich B; Grob PJ; Arrenbrecht S
Respiration; 1981; 41(4):248-57. PubMed ID: 6975491
[TBL] [Abstract][Full Text] [Related]
10. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor.
Kaplan RA; Curd JG; Deheer DH; Carson DA; Pangburn MK; Müller-Eberhard HJ; Vaughan JH
Arthritis Rheum; 1980 Aug; 23(8):911-20. PubMed ID: 6967727
[TBL] [Abstract][Full Text] [Related]
12. Activation of the complement and properdin systems in rheumatoid arthritis.
Ruddy S; Austen KF
Ann N Y Acad Sci; 1975 Jun; 256():96-104. PubMed ID: 1099964
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.
Romano C; Del Mastro A; Sellitto A; Solaro E; Esposito S; Cuomo G
Clin Rheumatol; 2018 Jun; 37(6):1695-1700. PubMed ID: 29362962
[TBL] [Abstract][Full Text] [Related]
14. Arthritis associated with chronic active hepatitis: complement activation and characterization of circulating immune complexes.
Wands JR; Alpert E; Isselbacher KJ
Gastroenterology; 1975 Dec; 69(6):1286-91. PubMed ID: 1193327
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
16. Activation of the alternative pathway of complement by immune complexes and degradation of these complexes by macrophages.
Daha MR
Ann Immunol (Paris); 1982; 133C(2):245-52. PubMed ID: 7114798
[No Abstract] [Full Text] [Related]
17. Monitoring the level of complement components during autologous blood stem cell transplantation in patients with malignant lymphomas.
Banyai A; Varga L; Barta A; Gopcsa L; Paloczi K
Cancer Immunol Immunother; 2004 Sep; 53(9):835-9. PubMed ID: 15052374
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
19. Pleural fluid complement, complement conversion, and immune complexes in immunologic and nonimmunologic diseases.
Hunder GG; McDuffie FC; Huston KA; Elveback LR; Hepper NG
J Lab Clin Med; 1977 Dec; 90(6):971-80. PubMed ID: 597373
[TBL] [Abstract][Full Text] [Related]
20. Binding of complement components C1q, C3, C4 and C5 to a model immune complex in ELISA.
Larsson A; Sjöquist J
J Immunol Methods; 1989 Apr; 119(1):103-9. PubMed ID: 2785142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
